 "Alembic Pharma receive USFDA approval to market drug for skin treatment")
Alembic Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market medication for treating actinic keratoses.
Aleor Dermaceuticals has received approval from the US Food and Drug Administration (USFDA) for Diclofenac Sodium topical gel, the drug firm said in a statement.
The product is indicated for the topical treatment of actinic keratoses.
According to IQVIA data, Diclofenac Sodium topical gel had an estimated market size of USD 10 million for twelve months ending March 2022.
Shares of Alembic Pharma were trading 0.56 per cent up at Rs 705.10 apeice on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)